阿尔茨海默病临床试验的全球化:当前特征和未来目标
Jeffrey L Cummings1, Josie Lindle2, Ibrahim Dalla2
1Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine at UNLV, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA.
International psychogeriatrics
|June 24, 2025
概括
阿尔茨海默病药物开发涉及全球182个试验和138种药物. 虽然许多地区参与,但低收入和中等收入国家在临床试验场所的代表人数不足,尽管患者人群很大,但这阻碍了招聘.
科学领域:
- * 临床试验管理和全球健康差异.
- * 制药开发和监管科学.
背景情况:
- *阿尔茨海默病 (AD) 药物开发管道广泛,有182个活跃试验和138种独特的药物.
- *全球参与阿尔茨海默病临床试验显著,涉及不同地理区域.
研究的目的:
- *分析正在进行的阿尔茨海默病临床试验的全球分布和特征.
- * 在全球AD试验中确定区域代表性和地点分布.
- * 评估低收入和中等收入国家的参与AD药物开发.
主要方法:
- *对阿尔茨海默病的活跃临床试验数据的分析.
- *检查试验阶段,地理分布,参与者数量和地点.
- *根据收入水平对参与国进行分类.
主要成果:
- *182个活跃的试验和138种药物正在阿尔茨海默病管道中.
- * 33%的试验是全球性的;第三阶段试验更有可能是全球性的 (73%).
- *北美在试验数量和试验地点方面处于领先地位;低收入和中等收入国家对试验地点的代表性很差 (7%).
结论:
- *阿尔茨海默病的临床试验涉及全球众多地区,北美拥有最多的试验和地点.
- * 低收入和中等收入国家在试验场所的代表显著不足,尽管有招聘潜力.
- *在代表性不足的地区发展基础设施可以改善全球阿尔茨海默病试验的招聘和获取.
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182
Clinical Trials
9.3K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
9.3K
Parkinson's Disease: Overview
722
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
722


